

Clinical Oversight Review Board (CORB) Criteria for Prescribing Guselkumab IV (Tremfya IV)

Notes:

- Quantity Limits: No (N/A – IV medication)
- Note: Quantity limits do apply to subcutaneous guselkumab
- ^ Adequate trial is defined as the following:
 - Biologics – 12 weeks
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-formulary **guselkumab IV (Tremfya IV)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **guselkumab IV (Tremfya IV)** will be covered under the medical benefit for 3 doses when the following criteria are met:

- Patient has a diagnosis of moderate to severe ulcerative colitis
- Prescriber is a gastroenterologist
- Patient is 18 years of age or older
- Patient has failed an adequate trial[^], has an intolerance^{*}, or has a contraindication to the following:
 - Infliximab product
 - Ustekinumab product (criteria based)